Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study

The safety and efficacy of lanadelumab for the prevention of hereditary angioedema (HAE) attacks have not been studied in Japanese patients. We report outcomes from a phase 3, multicenter, open-label study (NCT04180163) of lanadelumab in Japanese patients with HAE. Japanese patients with HAE aged ≥1...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of dermatology 2023-11, Vol.50 (11), p.1381-1391
Hauptverfasser:	Hide, Michihiro, Ohsawa, Isao, Nurse, Christina, Yu, Ming
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Angioedema Edema Monoclonal antibodies Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!